Register to chat with like-minded investors on our interactive forums.

Get Started

VSTM

Verastem (VSTM)

Verastem Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:VSTM

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
04/18/2024	4:05PM	Business Wire	Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer	NASDAQ:VSTM	Verastem Inc
04/04/2024	7:30AM	Business Wire	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:VSTM	Verastem Inc
03/18/2024	7:00AM	Business Wire	Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer	NASDAQ:VSTM	Verastem Inc
03/14/2024	4:05PM	Business Wire	Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates	NASDAQ:VSTM	Verastem Inc
03/11/2024	5:07PM	Edgar (US Regulatory)	Form SC TO-I/A - Tender offer statement by Issuer: [Amend]	NASDAQ:VSTM	Verastem Inc
03/11/2024	7:30AM	Business Wire	Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs	NASDAQ:VSTM	Verastem Inc
03/05/2024	5:27PM	Business Wire	Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer	NASDAQ:VSTM	Verastem Inc
03/05/2024	4:30PM	Business Wire	Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024	NASDAQ:VSTM	Verastem Inc
02/08/2024	4:22PM	Edgar (US Regulatory)	Form SC TO-I - Tender offer statement by Issuer	NASDAQ:VSTM	Verastem Inc
02/02/2024	9:49AM	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:VSTM	Verastem Inc
01/29/2024	4:01PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VSTM	Verastem Inc
01/29/2024	7:00AM	Business Wire	Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers	NASDAQ:VSTM	Verastem Inc
01/19/2024	7:54AM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VSTM	Verastem Inc
01/18/2024	4:00PM	Business Wire	Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)	NASDAQ:VSTM	Verastem Inc
01/11/2024	7:00AM	Business Wire	Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference	NASDAQ:VSTM	Verastem Inc
01/09/2024	4:03PM	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
01/08/2024	4:02PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VSTM	Verastem Inc
01/05/2024	7:00AM	Business Wire	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:VSTM	Verastem Inc
12/28/2023	4:04PM	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
12/21/2023	4:01PM	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
12/20/2023	4:01PM	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
12/20/2023	4:00PM	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
12/19/2023	4:01PM	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:VSTM	Verastem Inc
12/18/2023	7:00AM	Business Wire	Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics	NASDAQ:VSTM	Verastem Inc
12/13/2023	7:00AM	Business Wire	Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer	NASDAQ:VSTM	Verastem Inc
12/08/2023	4:10PM	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:VSTM	Verastem Inc
11/21/2023	12:15AM	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:VSTM	Verastem Inc
11/13/2023	7:00AM	Business Wire	New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach	NASDAQ:VSTM	Verastem Inc
11/08/2023	5:01PM	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:VSTM	Verastem Inc
11/08/2023	4:16PM	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VSTM	Verastem Inc

Showing the most relevant articles for your search:NASDAQ:VSTM

1 2 3 4 5 6 7 8 9 10 Next >>

Branded Legacy (PK)

Net Savings Link (PK)

FBEC Worldwide (PK)

Clean Vision (QB)

Buildablock (PK)

Therapeutic Solutions (PK)

Sunshine Biopharma

Ronn Motor (PK)

Enzolytics (PK)

Hannover House (PK)

Ubiquitech Software (PK)

BlackStar Enterprise (PK)

Delayed Upgrade Clock